Evaluation effects of nebulized gentamicin in exacerbation of chronic obstructive lung disease

Soltaninejad, Forogh; Kheiri, Soleiman; Habibian, R; Amra, Arshia; Asgari-Savadjani, Shahin

doi:10.4103/1735-1995.187278

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Soltaninejad and colleagues evaluated the effect of nebulized gentamycin (80 mg twice daily for 5 days) versus placebo on lung function given in patients with acute exacerbations of COPD. 70 Treatment with gentamicin resulted in significant improvements in FVC and FEV 1 versus placebo. Bruguera-Avila and colleagues evaluated the effect of nebulized colistin solution (80 mg twice daily for 1 year) on the number of severe exacerbations requiring hospitalizations and on the length of hospitalizations in patients with COPD who were colonized with P. aeruginosa.…”

Section: Nebulized Antibioticsmentioning

confidence: 95%

“…[64][65][66] However, very little research has been done to date on nebulized antibiotics in the treatment of COPD, with only four reports investigating the efficacy of nebulized antibiotics in patients with COPD. [67][68][69][70] Dal Negro and colleagues evaluated the effect of nebulized tobramycin (300 mg twice daily for 2 weeks) on the incidence of exacerbations and proinflammatory markers in patients with severe to very severe COPD who were colonized with Pseudomonas aeruginosa. 68 Tobramycin decreased the incidence of exacerbations by 42% when compared with the prior 6 months, and proinflammatory markers were significantly reduced after 2 weeks of tobramycin.…”

Section: Nebulized Antibioticsmentioning

confidence: 99%

See 1 more Smart Citation

<p>Nebulized Therapies in COPD: Past, Present, and the Future</p>

Barjaktarevic,

Milstone

2020

COPD

View full text Add to dashboard Cite

Current guidelines recommend inhalation therapy as the preferred route of drug administration for treating patients with chronic obstructive pulmonary disease (COPD). Inhalation devices consist of nebulizers and handheld inhalers, such as dry-powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and soft mist inhalers (SMIs). Although pMDIs, DPIs and SMIs may be appropriate for most patients with COPD, certain patient populations may have challenges with these devices. Patients who have cognitive, neuromuscular, or ventilatory impairments (and receive limited assistance from caregivers), as well as those with suboptimal peak inspiratory flow may not derive the full benefit from handheld inhalers. A considerable number of patients are not capable of producing a peak inspiratory flow rate to overcome the internal resistance of DPIs. Furthermore, patients may have difficulty coordinating inhalation with device actuation, which is required for pMDIs and SMIs. However, inhalation devices such as spacers and valved holding chambers can be used with pMDIs to increase the efficiency of aerosol delivery. Nebulized treatment provides patients with COPD an alternative administration route that avoids the need for inspiratory flow, manual dexterity, or complex hand-breath coordination. The recent approval of two nebulized long-acting muscarinic antagonists has added to the extensive range of nebulized therapies in COPD. Furthermore, with the availability of quieter and more portable nebulizer devices, nebulization may be a useful treatment option in the management of certain patient populations with COPD. The aim of this narrative review was to highlight recent updates and the treatment landscape in nebulized therapy and COPD. We first discuss the pathophysiology of patients with COPD and inhalation device considerations. Second, we review the updates on recently approved and newly marketed nebulized treatments, nebulized treatments currently in development, and technological advances in nebulizer devices. Finally, we discuss the current applications of nebulized therapy in patients with COPD.

show abstract

Section: Nebulized Antibioticsmentioning

confidence: 95%

Section: Nebulized Antibioticsmentioning

confidence: 99%

<p>Nebulized Therapies in COPD: Past, Present, and the Future</p>

Barjaktarevic,

Milstone

2020

COPD

View full text Add to dashboard Cite

show abstract

Antibiotics for exacerbations of chronic obstructive pulmonary disease

Vollenweider¹,

Frei

Steurer-Stey

et al. 2018

Cochrane Database of Systematic Reviews

102

108

View full text Add to dashboard Cite

Background Many patients with an exacerbation of chronic obstructive pulmonary disease (COPD) are treated with antibiotics. However, the value of antibiotics remains uncertain, as systematic reviews and clinical trials have shown conflicting results. Objectives To assess e ects of antibiotics on treatment failure as observed between seven days and one month a er treatment initiation (primary outcome) for management of acute COPD exacerbations, as well as their e ects on other patient-important outcomes (mortality, adverse events, length of hospital stay, time to next exacerbation).

show abstract